{
"NDC": [
{
"NDCCode": "83021-774-15",
"PackageDescription": "15 mL in 1 TUBE (83021-774-15) ",
"NDC11Code": "83021-0774-15",
"ProductNDC": "83021-774",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Aloe Barbadensis Leaf Extract, Propylene Glycol, Cetearyl Ethylhexanoate",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221014",
"EndMarketingDate": "20260203",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "1,2-HEXANEDIOL; ALLANTOIN; ALOE VERA LEAF; ARGAN OIL; BUTYLATED HYDROXYTOLUENE; BUTYROSPERMUM PARKII (SHEA) BUTTER UNSAPONIFIABLES; C12-20 ACID PEG-8 ESTER; CAPRYLYL GLYCOL; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; DECYL OLEATE; FRAGRANCE 13576; GLYCERIN; GRAPE SEED OIL; HEXAMETHYLENE DIISOCYANATE/TRIMETHYLOL HEXYLLACTONE CROSSPOLYMER; IMIDUREA; MEDIUM-CHAIN TRIGLYCERIDES; PROPYLENE GLYCOL; SILICON DIOXIDE; TOCOPHEROL; TROLAMINE; TROPOLONE; WATER",
"StrengthNumber": ".06; .015; .6; .075; .015; .15; .15; .0588; .12; .2999994; .0375; .15; .15; .1176; .045; .375; .6; .0024; .0000006; .12; .0012; 11.358",
"StrengthUnit": "g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; mL/15mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Deprecated",
"LastUpdate": "2026-02-04",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221014",
"EndMarketingDatePackage": "20260203",
"SamplePackage": "N"
},
{
"NDCCode": "10237-774-15",
"PackageDescription": "1 BOTTLE, SPRAY in 1 CARTON (10237-774-15) / 15 g in 1 BOTTLE, SPRAY",
"NDC11Code": "10237-0774-15",
"ProductNDC": "10237-774",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Rephresh Cooling",
"NonProprietaryName": "Hydrocortisone",
"DosageFormName": "SPRAY",
"RouteName": "TOPICAL",
"StartMarketingDate": "20180601",
"EndMarketingDate": "20250131",
"MarketingCategoryName": "OTC MONOGRAPH DRUG",
"ApplicationNumber": "M017",
"LabelerName": "Church & Dwight Co., Inc.",
"SubstanceName": "HYDROCORTISONE",
"StrengthNumber": "500",
"StrengthUnit": "g/g",
"Pharm_Classes": "Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",
"Status": "Deprecated",
"LastUpdate": "2025-02-04",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20180601",
"EndMarketingDatePackage": "20250131",
"SamplePackage": "N",
"IndicationAndUsage": "For the temporary relief of external feminine itching. Other uses of this product should be only under the advice and supervision of a doctor."
},
{
"NDCCode": "50268-774-15",
"PackageDescription": "50 BLISTER PACK in 1 BOX (50268-774-15) / 1 TABLET in 1 BLISTER PACK (50268-774-11) ",
"NDC11Code": "50268-0774-15",
"ProductNDC": "50268-774",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Tramadol Hydrochloride And Acetaminophen",
"NonProprietaryName": "Tramadol Hydrochloride And Acetaminophen",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20150114",
"EndMarketingDate": "20270331",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA090485",
"LabelerName": "AvPAK",
"SubstanceName": "TRAMADOL HYDROCHLORIDE; ACETAMINOPHEN",
"StrengthNumber": "37.5; 325",
"StrengthUnit": "mg/1; mg/1",
"Pharm_Classes": "Full Opioid Agonists [MoA], Opioid Agonist [EPC]",
"DEASchedule": "CIV",
"Status": "Active",
"LastUpdate": "2026-01-13",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20150114",
"EndMarketingDatePackage": "20270331",
"SamplePackage": "N",
"IndicationAndUsage": "Tramadol hydrochloride and acetaminophen tablets, USP are indicated for the short-term (five days or less) management of acute pain.",
"Description": "Tramadol hydrochloride and acetaminophen tablets, USP combine two analgesics, tramadol, USP 37.5 mg and acetaminophen, USP 325 mg. The chemical name for tramadol hydrochloride, USP is (±) cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:. The molecular weight of tramadol hydrochloride, USP is 299.84. Tramadol hydrochloride, USP is a white, bitter, crystalline and odorless powder. The chemical name for acetaminophen, USP is N-acetyl- p-aminophenol. Its structural formula is:. The molecular weight of acetaminophen, USP is 151.17. Acetaminophen, USP is an analgesic and antipyretic agent which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. Tramadol hydrochloride and acetaminophen tablets, USP contain 37.5 mg tramadol hydrochloride, USP and 325 mg acetaminophen, USP and are beige in color. Inactive ingredients in the tablets are carnauba wax, crospovidone, iron oxide black, iron oxide red, iron oxide yellow, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, polyvinyl alcohol, povidone, sodium starch glycolate, stearic acid, talc and titanium dioxide."
},
{
"NDCCode": "63187-774-15",
"PackageDescription": "1 TUBE in 1 CARTON (63187-774-15) > 15 g in 1 TUBE",
"NDC11Code": "63187-0774-15",
"ProductNDC": "63187-774",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Ketoconazole",
"NonProprietaryName": "Ketoconazole",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20021218",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA075638",
"LabelerName": "Proficient Rx LP",
"SubstanceName": "KETOCONAZOLE",
"StrengthNumber": "20",
"StrengthUnit": "mg/g",
"Pharm_Classes": "Azole Antifungal [EPC], Azoles [CS], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A5 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",
"Status": "Active",
"LastUpdate": "2022-04-21",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20161101",
"SamplePackage": "N",
"IndicationAndUsage": "Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.",
"Description": "Ketoconazole cream, 2% contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, sorbitan monostearate and stearyl alcohol. Ketoconazole is cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] piperazine and has the following structural formula. Molecular Formula: C26H28Cl2N4O4. Molecular Weight: 531.43."
},
{
"NDCCode": "70233-774-15",
"PackageDescription": "1 BOTTLE, SPRAY in 1 CARTON (70233-774-15) > 15 g in 1 BOTTLE, SPRAY",
"NDC11Code": "70233-0774-15",
"ProductNDC": "70233-774",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Rephresh Cooling",
"NonProprietaryName": "Hydrocortisone",
"DosageFormName": "SPRAY",
"RouteName": "TOPICAL",
"StartMarketingDate": "20180601",
"MarketingCategoryName": "OTC MONOGRAPH NOT FINAL",
"ApplicationNumber": "part348",
"LabelerName": "Fleet Laboratories LTD",
"SubstanceName": "HYDROCORTISONE",
"StrengthNumber": "500",
"StrengthUnit": "g/g",
"Status": "Deprecated",
"LastUpdate": "2020-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20191231",
"StartMarketingDatePackage": "20180601",
"SamplePackage": "N",
"IndicationAndUsage": "For the temporary relief of external feminine itching. Other uses of this product should be only under the advice and supervision of a doctor."
},
{
"NDCCode": "83021-300-01",
"PackageDescription": "200 mL in 1 TUBE (83021-300-01) ",
"NDC11Code": "83021-0300-01",
"ProductNDC": "83021-300",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Regul Oil",
"NonProprietaryName": "Propylene Glycol, Glyceryl Stearate Se, Humulus Lupulus (hops) Cone Extract",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221020",
"EndMarketingDate": "20280203",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M006",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "ARCTIUM LAPPA ROOT; POLYACRYLAMIDE (CROSSLINKED; 0.01-0.2 MOLE PERCENT BISACRYLAMIDE); LAURETH-7; PEG/PPG-20/6 DIMETHICONE; ALCOHOL; GLYCERIN; CETEARYL ETHYLHEXANOATE; LIMONENE, (+)-; PANTHENOL; IMIDUREA; FD&C YELLOW NO. 5; RIBOFLAVIN; PHENOXYETHANOL; FRAGRANCE 13576; WATER; CETOSTEARYL ALCOHOL; PROPYLENE GLYCOL; MINERAL OIL; ETHYLHEXYLGLYCERIN; METHYLCHLOROISOTHIAZOLINONE; METHYLISOTHIAZOLINONE; HOPS; TIOXOLONE; PROPYLPARABEN; YEAST, UNSPECIFIED; NIACINAMIDE; C13-14 ISOPARAFFIN; METHYLPARABEN; GLYCERYL STEARATE SE; TRIISOPROPANOLAMINE; PENTAERYTHRITOL TETRAKIS(3-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)PROPIONATE)",
"StrengthNumber": ".012; .8; .12; 1.372; .08; .048; 4; .08398; .1; .6; .00004; .00012; .0252; .6; 123.55598; 26; 10.148; 6; .0028; .045; .15; .0012; .3; .24; .023; .023; .48; .48; 7; .004; .0012",
"StrengthUnit": "g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Food Additives [CS], Fungal Proteins [CS], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221020",
"EndMarketingDatePackage": "20280203",
"SamplePackage": "N"
},
{
"NDCCode": "83021-305-50",
"PackageDescription": "50 mL in 1 TUBE (83021-305-50) ",
"NDC11Code": "83021-0305-50",
"ProductNDC": "83021-305",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Spa Line",
"NonProprietaryName": "Oryza Sativa (rice) Starch, Perlite, Palmitic Acid",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221014",
"EndMarketingDate": "20271013",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "FRAGRANCE 13576; GRAPE SEED OIL; GLYCERYL MONOSTEARATE; LINALOOL, (+/-)-; PHENOXYETHANOL; PROPYLENE GLYCOL; TITANIUM DIOXIDE; PALMITIC ACID; BUTYLATED HYDROXYTOLUENE; STARCH, RICE; ALCOHOL; C12-20 ACID PEG-8 ESTER; TROLAMINE; ISOMETHYL-.ALPHA.-IONONE; HYDROXYACETOPHENONE; PERLITE; GLYCERIN; ETHYLHEXYLGLYCERIN; .BETA.-CITRONELLOL, (R)-; WATER; STEARIC ACID; CETEARYL ETHYLHEXANOATE",
"StrengthNumber": ".15; .25; 3.5; .0114; .45; 1.5; .25; 1; .25; 5.5; 4.752; 1; .25; .00639; .25; 4; .0115; .05; .012; 25.04945; 1; .75",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL",
"Pharm_Classes": "Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221014",
"EndMarketingDatePackage": "20271013",
"SamplePackage": "N"
},
{
"NDCCode": "83021-400-50",
"PackageDescription": "50 mL in 1 BOTTLE, SPRAY (83021-400-50) ",
"NDC11Code": "83021-0400-50",
"ProductNDC": "83021-400",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Sodium Bicarbonate, Aloe Barbadensis Leaf Juice, Imidazolidinyl Urea",
"DosageFormName": "LIQUID",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221026",
"EndMarketingDate": "20270510",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "IMIDUREA; ALOE VERA LEAF; WATER",
"StrengthNumber": ".25; .15; 45.8293",
"StrengthUnit": "g/50mL; g/50mL; mL/50mL",
"Pharm_Classes": "Allergens [CS], Cell-mediated Immunity [PE], Increased Histamine Release [PE], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221026",
"EndMarketingDatePackage": "20270510",
"SamplePackage": "N"
},
{
"NDCCode": "83021-546-30",
"PackageDescription": "30 mL in 1 BOTTLE, DROPPER (83021-546-30) ",
"NDC11Code": "83021-0546-30",
"ProductNDC": "83021-546",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Dmae",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20230113",
"EndMarketingDate": "20270805",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "GLYCERIN; PHENOXYETHANOL; XANTHAN GUM; FRAGRANCE 13576; SORBITAN ISOSTEARATE; HYDROLYZED BOVINE ELASTIN (BASE; 1000 MW); LIMONENE, (+)-; TOCOPHEROL; HYDROXYCITRONELLAL; POLYSORBATE 60; LECITHIN, SOYBEAN; HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER (100000 MPA.S AT 1.5%); DEHYDROACETIC ACID; PROPANEDIOL; DICAPRYLYL ETHER; BENZOIC ACID; ASCORBYL GLUCOSIDE; WATER",
"StrengthNumber": ".555; .243; .09; .027; .024; .0012; .0009; .0003; .0006; .024; .45; .405; .021; 1.08; .9; .036; .15; 25.5564",
"StrengthUnit": "g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; mL/30mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230113",
"EndMarketingDatePackage": "20270805",
"SamplePackage": "N"
},
{
"NDCCode": "83021-750-50",
"PackageDescription": "50 mL in 1 JAR (83021-750-50) ",
"NDC11Code": "83021-0750-50",
"ProductNDC": "83021-750",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Ha Hyaluronic",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221017",
"EndMarketingDate": "20280116",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "ALLANTOIN; ALOE VERA LEAF; FRAGRANCE 13576; GLYCERYL MONOSTEARATE; TROLAMINE; BUTYLATED HYDROXYTOLUENE; PROPYLENE GLYCOL; CETYL ALCOHOL; TROPOLONE; TOCOPHEROL; DIMETHICONE; 1,2-HEXANEDIOL; IMIDUREA; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; CETEARYL ETHYLHEXANOATE; MEDIUM-CHAIN TRIGLYCERIDES; CAPRYLYL GLYCOL; OCTINOXATE; GLYCERIN; GLYCERYL STEARATE SE; WATER; C12-20 ACID PEG-8 ESTER; OXYBENZONE; DECYL OLEATE",
"StrengthNumber": ".05; 2.5; .225; .875; .3; .0535; 1.996; .0038; .004; .0004; .25; .198; .15; .25; 1.75; 1.5; .198; 3.4965; .4975; 1.5; 27.4065; 2.25; 2; 1.9996",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221017",
"EndMarketingDatePackage": "20280116",
"SamplePackage": "N"
},
{
"NDCCode": "83021-839-07",
"PackageDescription": "1.5 mL in 1 VIAL, SINGLE-USE (83021-839-07) ",
"NDC11Code": "83021-0839-07",
"ProductNDC": "83021-839",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Propanediol, Glycerin, Magnesium Ascorbyl Phosphate",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221018",
"EndMarketingDate": "20270113",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "GLYCERIN; PHENOXYETHANOL; FRAGRANCE 13576; DEHYDROACETIC ACID; WATER; PEG-8 CAPRYLIC/CAPRIC GLYCERIDES; ISOMETHYL-.ALPHA.-IONONE; EDETIC ACID; BENZOIC ACID; SORBIC ACID; BENZYL ALCOHOL; PROPANEDIOL; HYDROXYCITRONELLAL",
"StrengthNumber": ".01035; .0003; .00285; .00135; 1.16659425; .15; .00003; .000009; .0009; .0006; .01215; .15; .00006",
"StrengthUnit": "g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; mL/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Lead Chelating Activity [MoA], Lead Chelator [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Pediculicide [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221018",
"EndMarketingDatePackage": "20270113",
"SamplePackage": "N"
},
{
"NDCCode": "65015-774-61",
"PackageDescription": "100 kg in 1 DRUM (65015-774-61) ",
"NDC11Code": "65015-0774-61",
"ProductNDC": "65015-774",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Proguanil Hydrochloride",
"DosageFormName": "POWDER",
"StartMarketingDate": "20150219",
"EndMarketingDate": "20261201",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "MYLAN LABORATORIES LIMITED",
"SubstanceName": "PROGUANIL HYDROCHLORIDE",
"StrengthNumber": "1",
"StrengthUnit": "kg/kg",
"Status": "Unfinished",
"LastUpdate": "2022-01-04",
"StartMarketingDatePackage": "19-FEB-15",
"EndMarketingDatePackage": "01-DEC-26"
},
{
"NDCCode": "66259-936-15",
"PackageDescription": "1 KIT in 1 KIT (66259-936-15) * 10 mL in 1 VIAL, PLASTIC * 1 VIAL in 1 VIAL (66259-146-02) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (66259-146-01) ",
"NDC11Code": "66259-0936-15",
"ProductNDC": "66259-936",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Spy-mis Kit",
"NonProprietaryName": "Indocyanine Green",
"DosageFormName": "KIT",
"RouteName": "INTRADERMAL; INTRAVASCULAR; INTRAVENOUS",
"StartMarketingDate": "20190910",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA211580",
"LabelerName": "Novadaq Technologies Inc",
"Status": "Deprecated",
"LastUpdate": "2025-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20241231",
"StartMarketingDatePackage": "20190910",
"SamplePackage": "N",
"IndicationAndUsage": "SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: : 1 Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. (1.1) , 2 Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. (1.2) , 3 Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. (1.3) , 4 Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. (1.4).",
"Description": "SPY AGENT GREEN (indocyanine green for injection, USP) is a water soluble, optical imaging agent which is reconstituted with Sterile Water for Injection, USP, for intravenous, interstitial or intradermal use. Each vial contains a sterile, lyophilized, green powder containing 25 mg of indocyanine green with not more than 5% sodium iodide. Hydrochloric acid or sodium hydroxide may be used to adjust the pH prior to lyophilization. The chemical name for Indocyanine Green is 1 HBenz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt. Molecular Formula: C 43H 47N 2NaO 6S 2; Molecular Mass: 774.96 g/mol, with the following structural formula:. Indocyanine green has a peak spectral absorption at 805 nm. SPY AGENT GREEN has a pH of 5.5 to 7.5 when reconstituted with Sterile Water for Injection, USP."
},
{
"NDCCode": "66336-774-30",
"PackageDescription": "30 TABLET in 1 BOTTLE, PLASTIC (66336-774-30)",
"NDC11Code": "66336-0774-30",
"ProductNDC": "66336-774",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Meloxicam",
"NonProprietaryName": "Meloxicam",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20091201",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA077918",
"LabelerName": "Dispensing Solutions, Inc.",
"SubstanceName": "MELOXICAM",
"StrengthNumber": "15",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC]",
"Status": "Deprecated",
"LastUpdate": "2019-09-21",
"ProductNdcExcludeFlag": "E",
"ListingRecordCertifiedThrough": "20171231",
"IndicationAndUsage": "Meloxicam is a non-steroidal anti-inflammatory drug indicated for: : 1 Osteoarthritis (OA) (1.1) , 2 Rheumatoid Arthritis (RA) (1.2) .",
"Description": "Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow Meloxicam Tablets, USP contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C14H13N3O4S2 and it has the following structural formula:. Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)app = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2. Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam. The inactive ingredients in Meloxicam Tablets, USP include Colloidal Silicon Dioxide, Sodium Starch Glycolate, Lactose, Magnesium Stearate, Microcrystalline Cellulose, Povidone K-30, and Sodium Citrate."
},
{
"NDCCode": "66993-135-97",
"PackageDescription": "1 TRAY in 1 CARTON (66993-135-97) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER",
"NDC11Code": "66993-0135-97",
"ProductNDC": "66993-135",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Fluticasone Furoate And Vilanterol",
"NonProprietaryName": "Fluticasone Furoate And Vilanterol",
"DosageFormName": "POWDER",
"RouteName": "RESPIRATORY (INHALATION)",
"StartMarketingDate": "20220523",
"MarketingCategoryName": "NDA AUTHORIZED GENERIC",
"ApplicationNumber": "NDA204275",
"LabelerName": "Prasco Laboratories",
"SubstanceName": "FLUTICASONE FUROATE; VILANTEROL TRIFENATATE",
"StrengthNumber": "100; 25",
"StrengthUnit": "ug/1; ug/1",
"Pharm_Classes": "Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-06-15",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20220523",
"SamplePackage": "N",
"IndicationAndUsage": "Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta2-adrenergic agonist (LABA), indicated for: 1 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1.1), 2 the maintenance treatment of asthma in patients aged 5 years and older. (1.2).",
"Description": "Fluticasone Furoate/Vilanterol ELLIPTA is an inhalation powder drug product for delivery of a combination of fluticasone furoate (an ICS) and vilanterol (a LABA) to patients by oral inhalation. Fluticasone furoate, a synthetic trifluorinated corticosteroid, has the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate and the following chemical structure. Fluticasone furoate is a white powder with a molecular weight of 538.6, and the empirical formula is C27H29F3O6S. It is practically insoluble in water. Vilanterol trifenatate has the chemical name triphenylacetic acid-4-{(1R)-2-[(6-{2-[2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) and the following chemical structure. Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C24H33Cl2NO5C20H16O2. It is practically insoluble in water. Fluticasone furoate/vilanterol ELLIPTA is a light grey and pale blue plastic inhaler containing 2 foil blister strips. Each blister on one strip contains a white powder blend of micronized fluticasone furoate (50, 100 or 200 mcg) and lactose monohydrate (12.5, 12.4 or 12.3 mg, respectively), and each blister on the other strip contains a white powder blend of micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (12.34 mg). The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece. Under standardized in vitro test conditions, fluticasone furoate/vilanterol ELLIPTA delivers 46, 92 or 184 mcg of fluticasone furoate and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds. In adult patients with obstructive lung disease and severely compromised lung function (COPD with FEV1/FVC <70% and FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory failure), mean peak inspiratory flow through the ELLIPTA inhaler was 66.5 L/min (range: 43.5 to 81.0 L/min). In adult patients with severe asthma, mean peak inspiratory flow through the ELLIPTA inhaler was 96.6 L/min (range: 72.4 to 124.6 L/min). In pediatric patients with asthma aged 5 to 11 years, mean peak inspiratory flow through the ELLIPTA inhaler was 60.6 L/min (range: 36.3 to 82.5 L/min). The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile."
},
{
"NDCCode": "66993-136-97",
"PackageDescription": "1 TRAY in 1 CARTON (66993-136-97) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER",
"NDC11Code": "66993-0136-97",
"ProductNDC": "66993-136",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Fluticasone Furoate And Vilanterol",
"NonProprietaryName": "Fluticasone Furoate And Vilanterol",
"DosageFormName": "POWDER",
"RouteName": "RESPIRATORY (INHALATION)",
"StartMarketingDate": "20220523",
"MarketingCategoryName": "NDA AUTHORIZED GENERIC",
"ApplicationNumber": "NDA204275",
"LabelerName": "Prasco Laboratories",
"SubstanceName": "FLUTICASONE FUROATE; VILANTEROL TRIFENATATE",
"StrengthNumber": "200; 25",
"StrengthUnit": "ug/1; ug/1",
"Pharm_Classes": "Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",
"Status": "Active",
"LastUpdate": "2026-06-15",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20220523",
"SamplePackage": "N",
"IndicationAndUsage": "Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta2-adrenergic agonist (LABA), indicated for: 1 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1.1), 2 the maintenance treatment of asthma in patients aged 5 years and older. (1.2).",
"Description": "Fluticasone Furoate/Vilanterol ELLIPTA is an inhalation powder drug product for delivery of a combination of fluticasone furoate (an ICS) and vilanterol (a LABA) to patients by oral inhalation. Fluticasone furoate, a synthetic trifluorinated corticosteroid, has the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate and the following chemical structure. Fluticasone furoate is a white powder with a molecular weight of 538.6, and the empirical formula is C27H29F3O6S. It is practically insoluble in water. Vilanterol trifenatate has the chemical name triphenylacetic acid-4-{(1R)-2-[(6-{2-[2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) and the following chemical structure. Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C24H33Cl2NO5C20H16O2. It is practically insoluble in water. Fluticasone furoate/vilanterol ELLIPTA is a light grey and pale blue plastic inhaler containing 2 foil blister strips. Each blister on one strip contains a white powder blend of micronized fluticasone furoate (50, 100 or 200 mcg) and lactose monohydrate (12.5, 12.4 or 12.3 mg, respectively), and each blister on the other strip contains a white powder blend of micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (12.34 mg). The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece. Under standardized in vitro test conditions, fluticasone furoate/vilanterol ELLIPTA delivers 46, 92 or 184 mcg of fluticasone furoate and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds. In adult patients with obstructive lung disease and severely compromised lung function (COPD with FEV1/FVC <70% and FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory failure), mean peak inspiratory flow through the ELLIPTA inhaler was 66.5 L/min (range: 43.5 to 81.0 L/min). In adult patients with severe asthma, mean peak inspiratory flow through the ELLIPTA inhaler was 96.6 L/min (range: 72.4 to 124.6 L/min). In pediatric patients with asthma aged 5 to 11 years, mean peak inspiratory flow through the ELLIPTA inhaler was 60.6 L/min (range: 36.3 to 82.5 L/min). The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile."
},
{
"NDCCode": "70100-810-02",
"PackageDescription": "6 PACKAGE in 1 CARTON (70100-810-02) / 1 KIT in 1 PACKAGE * 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (70100-710-01) * 10 mL in 1 VIAL, PLASTIC (0409-4887-17) ",
"NDC11Code": "70100-0810-02",
"ProductNDC": "70100-810",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Ic-green",
"NonProprietaryName": "Indocyanine Green",
"DosageFormName": "KIT",
"StartMarketingDate": "20260415",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA011525",
"LabelerName": "Renew Pharmaceuticals Limited",
"Status": "Active",
"LastUpdate": "2026-04-15",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20260415",
"SamplePackage": "N",
"IndicationAndUsage": "Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older (1.1). Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older (1.2). Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer (1.3). Ophthalmic angiography in adults and pediatric patients (1.4).",
"Description": "IC-GREEN (indocyanine green for injection) is an optical imaging agent for intravenous or interstitial use. Each vial contains 10 mg or 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder. IC-GREEN has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP. The chemical name for Indocyanine Green is 1 HBenz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt. Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula. Indocyanine green has a peak spectral absorption at 805 nm in blood."
},
{
"NDCCode": "83021-033-01",
"PackageDescription": "250 mL in 1 BOTTLE, SPRAY (83021-033-01) ",
"NDC11Code": "83021-0033-01",
"ProductNDC": "83021-033",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona New Even",
"NonProprietaryName": "Lactic Acid, Citric Acid, Glycolic Acid",
"DosageFormName": "LOTION",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221013",
"EndMarketingDate": "20270113",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "FD&C BLUE NO. 1; LACTIC ACID; POLYOXYL 40 HYDROGENATED CASTOR OIL; TROLAMINE; .ALPHA.-HEXYLCINNAMALDEHYDE; LINALOOL, (+/-)-; BENZOIC ACID; PHENOXYETHANOL; GLYCOLIC ACID; WATER; ALLANTOIN; DEHYDROACETIC ACID; DIETHYLENE GLYCOL MONOETHYL ETHER; FRAGRANCE 13576; LIMONENE, (+)-; PROPYLENE GLYCOL",
"StrengthNumber": ".0005; 2.348125; 1.25; .5; .0150375; .0041025; .625; 2.5; 1.220625; 228.15635; .75; .25; .75; .075; .022755; 10.5",
"StrengthUnit": "g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; mL/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL",
"Pharm_Classes": "Acidifying Activity [MoA], Ammonium Ion Binding Activity [MoA], Nitrogen Binding Agent [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221013",
"EndMarketingDatePackage": "20270113",
"SamplePackage": "N"
},
{
"NDCCode": "83021-064-01",
"PackageDescription": "200 mL in 1 TUBE (83021-064-01) ",
"NDC11Code": "83021-0064-01",
"ProductNDC": "83021-064",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Vital Line",
"NonProprietaryName": "Hydrolyzed Collagen",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20230223",
"EndMarketingDate": "20261020",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "PHENOXYETHANOL; FRAGRANCE 13576; ETHYLHEXYLGLYCERIN; AVOBENZONE; .BETA.-SITOSTEROL; HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW); LINOLEIC ACID; TOCOPHEROL; MALVA SYLVESTRIS FLOWERING TOP; PAPAVER RHOEAS FLOWER; MEDIUM-CHAIN TRIGLYCERIDES; SHEA BUTTER; LINOLENIC ACID; POLYGLYCERYL-4 ISOSTEARATE; HEXYL LAURATE; WHITE WAX; HYDROGENATED CASTOR OIL; AMILOXATE; CETYL PEG/PPG-10/1 DIMETHICONE (HLB 4); SQUALANE; WATER; GLYCERIN; CETEARYL ETHYLHEXANOATE",
"StrengthNumber": "1.8; .8; .2; 2; .01; .2; .16; .08; .06; .04; 34; 4; .04; 3; 2.7; 1; 4; 4; 3; .01; 125.88; 7; 4",
"StrengthUnit": "g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL",
"Pharm_Classes": "Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-08-31",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230223",
"EndMarketingDatePackage": "20261020",
"SamplePackage": "N"
},
{
"NDCCode": "83021-187-01",
"PackageDescription": "200 mL in 1 TUBE (83021-187-01) ",
"NDC11Code": "83021-0187-01",
"ProductNDC": "83021-187",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Vital Line",
"NonProprietaryName": "Hydrolyzed Elastin, Hydrolysed Collagen, Cocoglycerides",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221025",
"EndMarketingDate": "20261020",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "AVOBENZONE; PHENOXYETHANOL; FRAGRANCE 13576; DEHYDROACETIC ACID; HYDROLYZED BOVINE ELASTIN (BASE; 1000 MW); OCTINOXATE; COCO-GLYCERIDES; GLYCERIN; HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW); CETOSTEARYL ALCOHOL; MEDIUM-CHAIN TRIGLYCERIDES; CETYL ALCOHOL; .ALPHA.-HEXYLCINNAMALDEHYDE; WATER; BENZOIC ACID; CENTAUREA CYANUS FLOWER; VIOLA ODORATA; LIMONENE, (+)-; POTASSIUM PHOSPHATE, UNSPECIFIED FORM; .BETA.-CITRONELLOL, (R)-; ISOMETHYL-.ALPHA.-IONONE; BUTYLATED HYDROXYTOLUENE",
"StrengthNumber": "2; 1.62; .98; .14; .03; 5; 8; 6.94; .6; 12.58; 12; 4; .16; 140; .24; .05; .05; .038; .006; .0056; .0054; .005",
"StrengthUnit": "g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL",
"Pharm_Classes": "Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221025",
"EndMarketingDatePackage": "20261020",
"SamplePackage": "N"
},
{
"NDCCode": "83021-401-50",
"PackageDescription": "50 mL in 1 BOTTLE (83021-401-50) ",
"NDC11Code": "83021-0401-50",
"ProductNDC": "83021-401",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Glycolic Acid, Citric Acid, Lactic Acid, Kojic Acid",
"DosageFormName": "LIQUID",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221104",
"EndMarketingDate": "20270701",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M006",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "GLYCOLIC ACID; KOJIC ACID; HEXYLRESORCINOL; ASCORBYL GLUCOSIDE; LACTIC ACID; PHENOXYETHANOL; PROPYLENE GLYCOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; ALCOHOL; AMMONIA; ISOPROPYL ALCOHOL; WATER; ETHYLHEXYLGLYCERIN; SALICYLIC ACID",
"StrengthNumber": "17; 2.5; 1; .25; 5; .225; .5; .34875; 6.3; 2.75; .75; 7.333; .025; 1",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL",
"Pharm_Classes": "Acidifying Activity [MoA]",
"Status": "Active",
"LastUpdate": "2023-09-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221104",
"EndMarketingDatePackage": "20270701",
"SamplePackage": "N"
},
{
"NDCCode": "83021-402-50",
"PackageDescription": "50 mL in 1 BOTTLE, GLASS (83021-402-50) ",
"NDC11Code": "83021-0402-50",
"ProductNDC": "83021-402",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Azelaic Acid, Salicylic Acid",
"DosageFormName": "LIQUID",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221026",
"EndMarketingDate": "20270908",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M006",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "AZELAIC ACID; POLYETHYLENE GLYCOL 400; PROPYLENE GLYCOL; ISOPROPYL ALCOHOL; WATER; SALICYLIC ACID; ALCOHOL",
"StrengthNumber": "7; 4.9965; 10; 2.7; 1.62; 1; 22.68",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; mL/50mL",
"Pharm_Classes": "Decreased Protein Synthesis [PE], Decreased Sebaceous Gland Activity [PE]",
"Status": "Active",
"LastUpdate": "2023-09-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221026",
"EndMarketingDatePackage": "20270908",
"SamplePackage": "N"
},
{
"NDCCode": "83021-495-20",
"PackageDescription": "20 mL in 1 BOTTLE, DROPPER (83021-495-20) ",
"NDC11Code": "83021-0495-20",
"ProductNDC": "83021-495",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Proteoglycan, Glycerin, Butylene Glycol",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221025",
"EndMarketingDate": "20270902",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "PHENOXYETHANOL; XANTHAN GUM; BENZOIC ACID; WATER; BUTYLENE GLYCOL; PROPANEDIOL; POLYSORBATE 20; EDETIC ACID; PROTEOGLYCAN 4; FRAGRANCE 13576; GLYCERIN; DEHYDROACETIC ACID",
"StrengthNumber": ".162; .08; .024; 16.4578; .46; .4; .2; .0002; .002; .03; 2; .014",
"StrengthUnit": "g/20mL; g/20mL; g/20mL; mL/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL",
"Pharm_Classes": "Allergens [CS], Ammonium Ion Binding Activity [MoA], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Lead Chelating Activity [MoA], Lead Chelator [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221025",
"EndMarketingDatePackage": "20270902",
"SamplePackage": "N"
},
{
"NDCCode": "83021-501-20",
"PackageDescription": "20 mL in 1 BOTTLE, DROPPER (83021-501-20) ",
"NDC11Code": "83021-0501-20",
"ProductNDC": "83021-501",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Ferulic Acid, Vitamin C, Dmae",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221013",
"EndMarketingDate": "20280124",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "ALCOHOL; GLYCERIN; LECITHIN, SOYBEAN; WATER; MALONDIALDEHYDE; POLYOXYL 35 CASTOR OIL; FRAGRANCE 13576; PEG-8 CAPRYLIC/CAPRIC GLYCERIDES; FERULIC ACID",
"StrengthNumber": ".96; .02; .12; 14.26; 2; .18; .02; 2; .1",
"StrengthUnit": "mL/20mL; g/20mL; g/20mL; mL/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL",
"Pharm_Classes": "Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221013",
"EndMarketingDatePackage": "20280124",
"SamplePackage": "N"
},
{
"NDCCode": "83021-551-50",
"PackageDescription": "50 mL in 1 BOTTLE (83021-551-50) ",
"NDC11Code": "83021-0551-50",
"ProductNDC": "83021-551",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubismed",
"NonProprietaryName": "Spf 50 Broad Spectrum Protection Fluid Emulsion",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221015",
"EndMarketingDate": "20270429",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M020",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; GLYCERIN; LINOLENIC ACID; TROMETHAMINE; OCTOCRYLENE; BUTYLATED HYDROXYTOLUENE; PROPYLENE GLYCOL; WATER; FRAGRANCE 13576; CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED); .ALPHA.-TOCOPHEROL; POLY(METHYL METHACRYLATE; 450000 MW); AVOBENZONE; TITANIUM DIOXIDE; PHENOXYETHANOL; POLYETHYLENE GLYCOL 400; LINOLEIC ACID; SILICON DIOXIDE; ANHYDROUS CITRIC ACID; ASCORBYL PALMITATE; ASCORBIC ACID; OCTISALATE; BEMOTRIZINOL; DIMETHICONE; OCTINOXATE; BUTYLENE GLYCOL; C20-22 ALCOHOLS; CHLORPHENESIN",
"StrengthNumber": ".025; .005; .00275; .22; 1.8; .0018; 2.5; 27.55; .3; .075; .006; 2.1; 1.8; .425; .35; .14225; .49725; .575; .00025; .00125; .00025; 1.8; 1.45; 1.25; 3.5982; 2.5; .3375; .1",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL",
"Pharm_Classes": "Acidifying Activity [MoA], Allergens [CS], Anti-coagulant [EPC], Ascorbic Acid [CS], Calcium Chelating Activity [MoA], Calculi Dissolution Agent [EPC], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Vitamin C [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221015",
"EndMarketingDatePackage": "20270429",
"SamplePackage": "N"
},
{
"NDCCode": "83021-553-60",
"PackageDescription": "60 mL in 1 JAR (83021-553-60) ",
"NDC11Code": "83021-0553-60",
"ProductNDC": "83021-553",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Dmae, Zirhafirm",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20230113",
"EndMarketingDate": "20280306",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "ALOE VERA LEAF; LINALOOL, (+/-)-; EUGENOL; PROPANEDIOL; BENZYL ALCOHOL; CETOSTEARYL ALCOHOL; DICAPRYLYL ETHER; SORBIC ACID; XANTHAN GUM; .BETA.-CITRONELLOL, (R)-; GLYCERYL MONOSTEARATE; FRAGRANCE 13576; SALICYLIC ACID; JUJUBE SEED; LECITHIN, SOYBEAN; BAICALIN; LEUZEA CARTHAMOIDES ROOT; WATER; LIMONENE, (+)-; HYDROXYCITRONELLAL; TOCOPHEROL; GLYCERIN; DECYL OLEATE; SHEA BUTTER",
"StrengthNumber": "5.988; .0006; .0006; 2.496; .456; 1.2; 1.5; .024; .18; .0006; 2.4; .114; .09; .048; .036; .012; .012; 33.2616; .006; .0024; .0018; 3.036; 3.9; 2.1",
"StrengthUnit": "g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; mL/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Pediculicide [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230113",
"EndMarketingDatePackage": "20280306",
"SamplePackage": "N"
},
{
"NDCCode": "83021-617-05",
"PackageDescription": "5 mL in 1 VIAL, GLASS (83021-617-05) ",
"NDC11Code": "83021-0617-05",
"ProductNDC": "83021-617",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona",
"NonProprietaryName": "Peg-40 Hydrogenated Castor Oil, Propylene Glycol, Allantoin",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221021",
"EndMarketingDate": "20270920",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M006",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "PROPYLPARABEN; ALLANTOIN; PANTHENOL; FD&C YELLOW NO. 5; PROPYLENE GLYCOL; ARCTIUM LAPPA ROOT; METHYLPARABEN; TIOXOLONE; WATER; ALCOHOL; POLYOXYL 40 HYDROGENATED CASTOR OIL; YEAST, UNSPECIFIED; ASCORBYL PALMITATE; RIBOFLAVIN; ETHYLPARABEN; TOCOPHEROL; CITRAL; LIMONENE, (+)-; POWDERED CELLULOSE; ISOPROPYL ALCOHOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; LEVOMENOL; FARNESOL; FRAGRANCE 13576; PHENOXYETHANOL; BUTYLPARABEN; NIACINAMIDE",
"StrengthNumber": ".0000001; .0125; .0025; .00001; .0069; .000035; .00500065; .01; 3.12515585; 1.756; .02; .01725; .00005; .000003; .00000015; .000001; .000097; .002095; .0003; .0006; .017; .0045; .0005; .01; .000003; .00000025; .0001",
"StrengthUnit": "g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; mL/5mL; mL/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Fungal Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221021",
"EndMarketingDatePackage": "20270920",
"SamplePackage": "N"
},
{
"NDCCode": "83021-624-10",
"PackageDescription": "10 mL in 1 BOTTLE, WITH APPLICATOR (83021-624-10) ",
"NDC11Code": "83021-0624-10",
"ProductNDC": "83021-624",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Regul Oil",
"NonProprietaryName": "Peg-40 Hydrogenated Castor Oil, Propylene Glycol, Arctium Majus Root Extract",
"DosageFormName": "CONCENTRATE",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221021",
"EndMarketingDate": "20270707",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M006",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "ALCOHOL; POLYOXYL 40 HYDROGENATED CASTOR OIL; YEAST, UNSPECIFIED; PROPYLENE GLYCOL; ARCTIUM LAPPA ROOT; ALLANTOIN; POWDERED CELLULOSE; PROPYLPARABEN; TOCOPHEROL; FRAGRANCE 13576; ETHYLPARABEN; ASCORBYL PALMITATE; WATER; TIOXOLONE; LEVOMENOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; ISOPROPYL ALCOHOL; FARNESOL; METHYLPARABEN; PANTHENOL; PHENOXYETHANOL; BUTYLPARABEN; NIACINAMIDE; RIBOFLAVIN; CITRAL; LIMONENE, (+)-; FD&C YELLOW NO. 5",
"StrengthNumber": "3.512; .04; .0345; .0138; .00007; .025; .0006; .0000002; .000002; .02; .0000003; .0001; 6.2503117; .02; .009; .034; .0012; .001; .0100013; .005; .000006; .0000005; .0002; .000006; .000194; .00419; .00002",
"StrengthUnit": "mL/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; mL/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Fungal Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221021",
"EndMarketingDatePackage": "20270707",
"SamplePackage": "N"
},
{
"NDCCode": "83021-686-50",
"PackageDescription": "50 mL in 1 BOTTLE (83021-686-50) ",
"NDC11Code": "83021-0686-50",
"ProductNDC": "83021-686",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Protective Line",
"NonProprietaryName": "Ethylhexyl Methoxycinnamate, Butyl Methoxydibenzoylmethane, Ethylhexyl Salicylate, Octocrylene",
"DosageFormName": "CREAM",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221102",
"EndMarketingDate": "20280309",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M020",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "OCTINOXATE; TITANIUM DIOXIDE; CHLORPHENESIN; OCTISALATE; BUTYLENE GLYCOL; PROPYLENE GLYCOL; POLY(METHYL METHACRYLATE; 450000 MW); WATER; SILICON DIOXIDE; BUTYLATED HYDROXYTOLUENE; DIMETHICONE; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; C20-22 ALCOHOLS; FRAGRANCE 13576; CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED); TROMETHAMINE; BEMOTRIZINOL; POLYETHYLENE GLYCOL 400; ASCORBYL PALMITATE; PHENOXYETHANOL; OCTOCRYLENE; AVOBENZONE; LINOLENIC ACID; ASCORBIC ACID; TOCOPHEROL; LINOLEIC ACID; GLYCERIN",
"StrengthNumber": "3.5982; .425; .1; 1.8; 2.5; 2.5; 2.1; 27.55; .575; .0018; 1.25; .025; .3375; .3; .075; .22; 1.45; .14225; .00125; .35; 1.8; 1.8; .00275; .00025; .006; .49725; .005",
"StrengthUnit": "g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL",
"Pharm_Classes": "Allergens [CS], Ascorbic Acid [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Vitamin C [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221102",
"EndMarketingDatePackage": "20280309",
"SamplePackage": "N"
},
{
"NDCCode": "83021-692-01",
"PackageDescription": "250 mL in 1 BOTTLE, SPRAY (83021-692-01) ",
"NDC11Code": "83021-0692-01",
"ProductNDC": "83021-692",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Anubis Barcelona Total Hydrating",
"NonProprietaryName": "Betaine, Glycerin, Polysorbate 20",
"DosageFormName": "LOTION",
"RouteName": "TOPICAL",
"StartMarketingDate": "20221013",
"EndMarketingDate": "20270912",
"MarketingCategoryName": "OTC MONOGRAPH FINAL",
"ApplicationNumber": "M016",
"LabelerName": "ANUBIS COSMETICS SL",
"SubstanceName": "BETAINE; FRAGRANCE 13576; FD&C BLUE NO. 1; BENZOIC ACID; GLYCERIN; PHENOXYETHANOL; ETHYLHEXYLGLYCERIN; POLYSORBATE 20; WATER; IMIDUREA",
"StrengthNumber": "5; .125; .00025; 1.75; 5; 2.25; .125; 2.75; 232.139; .75",
"StrengthUnit": "g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; mL/250mL; g/250mL",
"Pharm_Classes": "Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Methylating Activity [MoA], Methylating Agent [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]",
"Status": "Active",
"LastUpdate": "2023-09-05",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20221013",
"EndMarketingDatePackage": "20270912",
"SamplePackage": "N"
}
]
}
<?xml version="1.0" encoding="utf-8"?>
<NDCList>
<NDC>
<NDCCode>83021-774-15</NDCCode>
<PackageDescription>15 mL in 1 TUBE (83021-774-15) </PackageDescription>
<NDC11Code>83021-0774-15</NDC11Code>
<ProductNDC>83021-774</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Aloe Barbadensis Leaf Extract, Propylene Glycol, Cetearyl Ethylhexanoate</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221014</StartMarketingDate>
<EndMarketingDate>20260203</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>1,2-HEXANEDIOL; ALLANTOIN; ALOE VERA LEAF; ARGAN OIL; BUTYLATED HYDROXYTOLUENE; BUTYROSPERMUM PARKII (SHEA) BUTTER UNSAPONIFIABLES; C12-20 ACID PEG-8 ESTER; CAPRYLYL GLYCOL; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; DECYL OLEATE; FRAGRANCE 13576; GLYCERIN; GRAPE SEED OIL; HEXAMETHYLENE DIISOCYANATE/TRIMETHYLOL HEXYLLACTONE CROSSPOLYMER; IMIDUREA; MEDIUM-CHAIN TRIGLYCERIDES; PROPYLENE GLYCOL; SILICON DIOXIDE; TOCOPHEROL; TROLAMINE; TROPOLONE; WATER</SubstanceName>
<StrengthNumber>.06; .015; .6; .075; .015; .15; .15; .0588; .12; .2999994; .0375; .15; .15; .1176; .045; .375; .6; .0024; .0000006; .12; .0012; 11.358</StrengthNumber>
<StrengthUnit>g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; g/15mL; mL/15mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2026-02-04</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221014</StartMarketingDatePackage>
<EndMarketingDatePackage>20260203</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>10237-774-15</NDCCode>
<PackageDescription>1 BOTTLE, SPRAY in 1 CARTON (10237-774-15) / 15 g in 1 BOTTLE, SPRAY</PackageDescription>
<NDC11Code>10237-0774-15</NDC11Code>
<ProductNDC>10237-774</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Rephresh Cooling</ProprietaryName>
<NonProprietaryName>Hydrocortisone</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20180601</StartMarketingDate>
<EndMarketingDate>20250131</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH DRUG</MarketingCategoryName>
<ApplicationNumber>M017</ApplicationNumber>
<LabelerName>Church & Dwight Co., Inc.</LabelerName>
<SubstanceName>HYDROCORTISONE</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Pharm_Classes>Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2025-02-04</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20180601</StartMarketingDatePackage>
<EndMarketingDatePackage>20250131</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>For the temporary relief of external feminine itching. Other uses of this product should be only under the advice and supervision of a doctor.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>50268-774-15</NDCCode>
<PackageDescription>50 BLISTER PACK in 1 BOX (50268-774-15) / 1 TABLET in 1 BLISTER PACK (50268-774-11) </PackageDescription>
<NDC11Code>50268-0774-15</NDC11Code>
<ProductNDC>50268-774</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Tramadol Hydrochloride And Acetaminophen</ProprietaryName>
<NonProprietaryName>Tramadol Hydrochloride And Acetaminophen</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20150114</StartMarketingDate>
<EndMarketingDate>20270331</EndMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA090485</ApplicationNumber>
<LabelerName>AvPAK</LabelerName>
<SubstanceName>TRAMADOL HYDROCHLORIDE; ACETAMINOPHEN</SubstanceName>
<StrengthNumber>37.5; 325</StrengthNumber>
<StrengthUnit>mg/1; mg/1</StrengthUnit>
<Pharm_Classes>Full Opioid Agonists [MoA], Opioid Agonist [EPC]</Pharm_Classes>
<DEASchedule>CIV</DEASchedule>
<Status>Active</Status>
<LastUpdate>2026-01-13</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20150114</StartMarketingDatePackage>
<EndMarketingDatePackage>20270331</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Tramadol hydrochloride and acetaminophen tablets, USP are indicated for the short-term (five days or less) management of acute pain.</IndicationAndUsage>
<Description>Tramadol hydrochloride and acetaminophen tablets, USP combine two analgesics, tramadol, USP 37.5 mg and acetaminophen, USP 325 mg. The chemical name for tramadol hydrochloride, USP is (±) cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:. The molecular weight of tramadol hydrochloride, USP is 299.84. Tramadol hydrochloride, USP is a white, bitter, crystalline and odorless powder. The chemical name for acetaminophen, USP is N-acetyl- p-aminophenol. Its structural formula is:. The molecular weight of acetaminophen, USP is 151.17. Acetaminophen, USP is an analgesic and antipyretic agent which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. Tramadol hydrochloride and acetaminophen tablets, USP contain 37.5 mg tramadol hydrochloride, USP and 325 mg acetaminophen, USP and are beige in color. Inactive ingredients in the tablets are carnauba wax, crospovidone, iron oxide black, iron oxide red, iron oxide yellow, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, polyvinyl alcohol, povidone, sodium starch glycolate, stearic acid, talc and titanium dioxide.</Description>
</NDC>
<NDC>
<NDCCode>63187-774-15</NDCCode>
<PackageDescription>1 TUBE in 1 CARTON (63187-774-15) > 15 g in 1 TUBE</PackageDescription>
<NDC11Code>63187-0774-15</NDC11Code>
<ProductNDC>63187-774</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Ketoconazole</ProprietaryName>
<NonProprietaryName>Ketoconazole</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20021218</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA075638</ApplicationNumber>
<LabelerName>Proficient Rx LP</LabelerName>
<SubstanceName>KETOCONAZOLE</SubstanceName>
<StrengthNumber>20</StrengthNumber>
<StrengthUnit>mg/g</StrengthUnit>
<Pharm_Classes>Azole Antifungal [EPC], Azoles [CS], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A5 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2022-04-21</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20161101</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.</IndicationAndUsage>
<Description>Ketoconazole cream, 2% contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, sorbitan monostearate and stearyl alcohol. Ketoconazole is cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] piperazine and has the following structural formula. Molecular Formula: C26H28Cl2N4O4. Molecular Weight: 531.43.</Description>
</NDC>
<NDC>
<NDCCode>70233-774-15</NDCCode>
<PackageDescription>1 BOTTLE, SPRAY in 1 CARTON (70233-774-15) > 15 g in 1 BOTTLE, SPRAY</PackageDescription>
<NDC11Code>70233-0774-15</NDC11Code>
<ProductNDC>70233-774</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Rephresh Cooling</ProprietaryName>
<NonProprietaryName>Hydrocortisone</NonProprietaryName>
<DosageFormName>SPRAY</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20180601</StartMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH NOT FINAL</MarketingCategoryName>
<ApplicationNumber>part348</ApplicationNumber>
<LabelerName>Fleet Laboratories LTD</LabelerName>
<SubstanceName>HYDROCORTISONE</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Deprecated</Status>
<LastUpdate>2020-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20191231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20180601</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>For the temporary relief of external feminine itching. Other uses of this product should be only under the advice and supervision of a doctor.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>83021-300-01</NDCCode>
<PackageDescription>200 mL in 1 TUBE (83021-300-01) </PackageDescription>
<NDC11Code>83021-0300-01</NDC11Code>
<ProductNDC>83021-300</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Regul Oil</ProprietaryName>
<NonProprietaryName>Propylene Glycol, Glyceryl Stearate Se, Humulus Lupulus (hops) Cone Extract</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221020</StartMarketingDate>
<EndMarketingDate>20280203</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M006</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>ARCTIUM LAPPA ROOT; POLYACRYLAMIDE (CROSSLINKED; 0.01-0.2 MOLE PERCENT BISACRYLAMIDE); LAURETH-7; PEG/PPG-20/6 DIMETHICONE; ALCOHOL; GLYCERIN; CETEARYL ETHYLHEXANOATE; LIMONENE, (+)-; PANTHENOL; IMIDUREA; FD&C YELLOW NO. 5; RIBOFLAVIN; PHENOXYETHANOL; FRAGRANCE 13576; WATER; CETOSTEARYL ALCOHOL; PROPYLENE GLYCOL; MINERAL OIL; ETHYLHEXYLGLYCERIN; METHYLCHLOROISOTHIAZOLINONE; METHYLISOTHIAZOLINONE; HOPS; TIOXOLONE; PROPYLPARABEN; YEAST, UNSPECIFIED; NIACINAMIDE; C13-14 ISOPARAFFIN; METHYLPARABEN; GLYCERYL STEARATE SE; TRIISOPROPANOLAMINE; PENTAERYTHRITOL TETRAKIS(3-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)PROPIONATE)</SubstanceName>
<StrengthNumber>.012; .8; .12; 1.372; .08; .048; 4; .08398; .1; .6; .00004; .00012; .0252; .6; 123.55598; 26; 10.148; 6; .0028; .045; .15; .0012; .3; .24; .023; .023; .48; .48; 7; .004; .0012</StrengthNumber>
<StrengthUnit>g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Dietary Proteins [CS], Food Additives [CS], Fungal Proteins [CS], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Plant Allergenic Extract [EPC], Plant Proteins [CS], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221020</StartMarketingDatePackage>
<EndMarketingDatePackage>20280203</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-305-50</NDCCode>
<PackageDescription>50 mL in 1 TUBE (83021-305-50) </PackageDescription>
<NDC11Code>83021-0305-50</NDC11Code>
<ProductNDC>83021-305</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Spa Line</ProprietaryName>
<NonProprietaryName>Oryza Sativa (rice) Starch, Perlite, Palmitic Acid</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221014</StartMarketingDate>
<EndMarketingDate>20271013</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>FRAGRANCE 13576; GRAPE SEED OIL; GLYCERYL MONOSTEARATE; LINALOOL, (+/-)-; PHENOXYETHANOL; PROPYLENE GLYCOL; TITANIUM DIOXIDE; PALMITIC ACID; BUTYLATED HYDROXYTOLUENE; STARCH, RICE; ALCOHOL; C12-20 ACID PEG-8 ESTER; TROLAMINE; ISOMETHYL-.ALPHA.-IONONE; HYDROXYACETOPHENONE; PERLITE; GLYCERIN; ETHYLHEXYLGLYCERIN; .BETA.-CITRONELLOL, (R)-; WATER; STEARIC ACID; CETEARYL ETHYLHEXANOATE</SubstanceName>
<StrengthNumber>.15; .25; 3.5; .0114; .45; 1.5; .25; 1; .25; 5.5; 4.752; 1; .25; .00639; .25; 4; .0115; .05; .012; 25.04945; 1; .75</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221014</StartMarketingDatePackage>
<EndMarketingDatePackage>20271013</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-400-50</NDCCode>
<PackageDescription>50 mL in 1 BOTTLE, SPRAY (83021-400-50) </PackageDescription>
<NDC11Code>83021-0400-50</NDC11Code>
<ProductNDC>83021-400</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Sodium Bicarbonate, Aloe Barbadensis Leaf Juice, Imidazolidinyl Urea</NonProprietaryName>
<DosageFormName>LIQUID</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221026</StartMarketingDate>
<EndMarketingDate>20270510</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>IMIDUREA; ALOE VERA LEAF; WATER</SubstanceName>
<StrengthNumber>.25; .15; 45.8293</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; mL/50mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Cell-mediated Immunity [PE], Increased Histamine Release [PE], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221026</StartMarketingDatePackage>
<EndMarketingDatePackage>20270510</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-546-30</NDCCode>
<PackageDescription>30 mL in 1 BOTTLE, DROPPER (83021-546-30) </PackageDescription>
<NDC11Code>83021-0546-30</NDC11Code>
<ProductNDC>83021-546</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Dmae</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20230113</StartMarketingDate>
<EndMarketingDate>20270805</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>GLYCERIN; PHENOXYETHANOL; XANTHAN GUM; FRAGRANCE 13576; SORBITAN ISOSTEARATE; HYDROLYZED BOVINE ELASTIN (BASE; 1000 MW); LIMONENE, (+)-; TOCOPHEROL; HYDROXYCITRONELLAL; POLYSORBATE 60; LECITHIN, SOYBEAN; HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER (100000 MPA.S AT 1.5%); DEHYDROACETIC ACID; PROPANEDIOL; DICAPRYLYL ETHER; BENZOIC ACID; ASCORBYL GLUCOSIDE; WATER</SubstanceName>
<StrengthNumber>.555; .243; .09; .027; .024; .0012; .0009; .0003; .0006; .024; .45; .405; .021; 1.08; .9; .036; .15; 25.5564</StrengthNumber>
<StrengthUnit>g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; g/30mL; mL/30mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230113</StartMarketingDatePackage>
<EndMarketingDatePackage>20270805</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-750-50</NDCCode>
<PackageDescription>50 mL in 1 JAR (83021-750-50) </PackageDescription>
<NDC11Code>83021-0750-50</NDC11Code>
<ProductNDC>83021-750</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Ha Hyaluronic</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221017</StartMarketingDate>
<EndMarketingDate>20280116</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>ALLANTOIN; ALOE VERA LEAF; FRAGRANCE 13576; GLYCERYL MONOSTEARATE; TROLAMINE; BUTYLATED HYDROXYTOLUENE; PROPYLENE GLYCOL; CETYL ALCOHOL; TROPOLONE; TOCOPHEROL; DIMETHICONE; 1,2-HEXANEDIOL; IMIDUREA; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; CETEARYL ETHYLHEXANOATE; MEDIUM-CHAIN TRIGLYCERIDES; CAPRYLYL GLYCOL; OCTINOXATE; GLYCERIN; GLYCERYL STEARATE SE; WATER; C12-20 ACID PEG-8 ESTER; OXYBENZONE; DECYL OLEATE</SubstanceName>
<StrengthNumber>.05; 2.5; .225; .875; .3; .0535; 1.996; .0038; .004; .0004; .25; .198; .15; .25; 1.75; 1.5; .198; 3.4965; .4975; 1.5; 27.4065; 2.25; 2; 1.9996</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221017</StartMarketingDatePackage>
<EndMarketingDatePackage>20280116</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-839-07</NDCCode>
<PackageDescription>1.5 mL in 1 VIAL, SINGLE-USE (83021-839-07) </PackageDescription>
<NDC11Code>83021-0839-07</NDC11Code>
<ProductNDC>83021-839</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Propanediol, Glycerin, Magnesium Ascorbyl Phosphate</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221018</StartMarketingDate>
<EndMarketingDate>20270113</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>GLYCERIN; PHENOXYETHANOL; FRAGRANCE 13576; DEHYDROACETIC ACID; WATER; PEG-8 CAPRYLIC/CAPRIC GLYCERIDES; ISOMETHYL-.ALPHA.-IONONE; EDETIC ACID; BENZOIC ACID; SORBIC ACID; BENZYL ALCOHOL; PROPANEDIOL; HYDROXYCITRONELLAL</SubstanceName>
<StrengthNumber>.01035; .0003; .00285; .00135; 1.16659425; .15; .00003; .000009; .0009; .0006; .01215; .15; .00006</StrengthNumber>
<StrengthUnit>g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; mL/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL; g/1.5mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Lead Chelating Activity [MoA], Lead Chelator [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Pediculicide [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221018</StartMarketingDatePackage>
<EndMarketingDatePackage>20270113</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>65015-774-61</NDCCode>
<PackageDescription>100 kg in 1 DRUM (65015-774-61) </PackageDescription>
<NDC11Code>65015-0774-61</NDC11Code>
<ProductNDC>65015-774</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Proguanil Hydrochloride</NonProprietaryName>
<DosageFormName>POWDER</DosageFormName>
<StartMarketingDate>20150219</StartMarketingDate>
<EndMarketingDate>20261201</EndMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>MYLAN LABORATORIES LIMITED</LabelerName>
<SubstanceName>PROGUANIL HYDROCHLORIDE</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>kg/kg</StrengthUnit>
<Status>Unfinished</Status>
<LastUpdate>2022-01-04</LastUpdate>
<StartMarketingDatePackage>19-FEB-15</StartMarketingDatePackage>
<EndMarketingDatePackage>01-DEC-26</EndMarketingDatePackage>
</NDC>
<NDC>
<NDCCode>66259-936-15</NDCCode>
<PackageDescription>1 KIT in 1 KIT (66259-936-15) * 10 mL in 1 VIAL, PLASTIC * 1 VIAL in 1 VIAL (66259-146-02) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (66259-146-01) </PackageDescription>
<NDC11Code>66259-0936-15</NDC11Code>
<ProductNDC>66259-936</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Spy-mis Kit</ProprietaryName>
<NonProprietaryName>Indocyanine Green</NonProprietaryName>
<DosageFormName>KIT</DosageFormName>
<RouteName>INTRADERMAL; INTRAVASCULAR; INTRAVENOUS</RouteName>
<StartMarketingDate>20190910</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA211580</ApplicationNumber>
<LabelerName>Novadaq Technologies Inc</LabelerName>
<Status>Deprecated</Status>
<LastUpdate>2025-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20241231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190910</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: : 1 Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. (1.1) , 2 Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. (1.2) , 3 Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. (1.3) , 4 Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. (1.4).</IndicationAndUsage>
<Description>SPY AGENT GREEN (indocyanine green for injection, USP) is a water soluble, optical imaging agent which is reconstituted with Sterile Water for Injection, USP, for intravenous, interstitial or intradermal use. Each vial contains a sterile, lyophilized, green powder containing 25 mg of indocyanine green with not more than 5% sodium iodide. Hydrochloric acid or sodium hydroxide may be used to adjust the pH prior to lyophilization. The chemical name for Indocyanine Green is 1 HBenz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt. Molecular Formula: C 43H 47N 2NaO 6S 2; Molecular Mass: 774.96 g/mol, with the following structural formula:. Indocyanine green has a peak spectral absorption at 805 nm. SPY AGENT GREEN has a pH of 5.5 to 7.5 when reconstituted with Sterile Water for Injection, USP.</Description>
</NDC>
<NDC>
<NDCCode>66336-774-30</NDCCode>
<PackageDescription>30 TABLET in 1 BOTTLE, PLASTIC (66336-774-30)</PackageDescription>
<NDC11Code>66336-0774-30</NDC11Code>
<ProductNDC>66336-774</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Meloxicam</ProprietaryName>
<NonProprietaryName>Meloxicam</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20091201</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA077918</ApplicationNumber>
<LabelerName>Dispensing Solutions, Inc.</LabelerName>
<SubstanceName>MELOXICAM</SubstanceName>
<StrengthNumber>15</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2019-09-21</LastUpdate>
<ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
<IndicationAndUsage>Meloxicam is a non-steroidal anti-inflammatory drug indicated for: : 1 Osteoarthritis (OA) (1.1) , 2 Rheumatoid Arthritis (RA) (1.2) .</IndicationAndUsage>
<Description>Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow Meloxicam Tablets, USP contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C14H13N3O4S2 and it has the following structural formula:. Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)app = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2. Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam. The inactive ingredients in Meloxicam Tablets, USP include Colloidal Silicon Dioxide, Sodium Starch Glycolate, Lactose, Magnesium Stearate, Microcrystalline Cellulose, Povidone K-30, and Sodium Citrate.</Description>
</NDC>
<NDC>
<NDCCode>66993-135-97</NDCCode>
<PackageDescription>1 TRAY in 1 CARTON (66993-135-97) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER</PackageDescription>
<NDC11Code>66993-0135-97</NDC11Code>
<ProductNDC>66993-135</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Fluticasone Furoate And Vilanterol</ProprietaryName>
<NonProprietaryName>Fluticasone Furoate And Vilanterol</NonProprietaryName>
<DosageFormName>POWDER</DosageFormName>
<RouteName>RESPIRATORY (INHALATION)</RouteName>
<StartMarketingDate>20220523</StartMarketingDate>
<MarketingCategoryName>NDA AUTHORIZED GENERIC</MarketingCategoryName>
<ApplicationNumber>NDA204275</ApplicationNumber>
<LabelerName>Prasco Laboratories</LabelerName>
<SubstanceName>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</SubstanceName>
<StrengthNumber>100; 25</StrengthNumber>
<StrengthUnit>ug/1; ug/1</StrengthUnit>
<Pharm_Classes>Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-06-15</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20220523</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta2-adrenergic agonist (LABA), indicated for: 1 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1.1), 2 the maintenance treatment of asthma in patients aged 5 years and older. (1.2).</IndicationAndUsage>
<Description>Fluticasone Furoate/Vilanterol ELLIPTA is an inhalation powder drug product for delivery of a combination of fluticasone furoate (an ICS) and vilanterol (a LABA) to patients by oral inhalation. Fluticasone furoate, a synthetic trifluorinated corticosteroid, has the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate and the following chemical structure. Fluticasone furoate is a white powder with a molecular weight of 538.6, and the empirical formula is C27H29F3O6S. It is practically insoluble in water. Vilanterol trifenatate has the chemical name triphenylacetic acid-4-{(1R)-2-[(6-{2-[2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) and the following chemical structure. Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C24H33Cl2NO5C20H16O2. It is practically insoluble in water. Fluticasone furoate/vilanterol ELLIPTA is a light grey and pale blue plastic inhaler containing 2 foil blister strips. Each blister on one strip contains a white powder blend of micronized fluticasone furoate (50, 100 or 200 mcg) and lactose monohydrate (12.5, 12.4 or 12.3 mg, respectively), and each blister on the other strip contains a white powder blend of micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (12.34 mg). The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece. Under standardized in vitro test conditions, fluticasone furoate/vilanterol ELLIPTA delivers 46, 92 or 184 mcg of fluticasone furoate and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds. In adult patients with obstructive lung disease and severely compromised lung function (COPD with FEV1/FVC <70% and FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory failure), mean peak inspiratory flow through the ELLIPTA inhaler was 66.5 L/min (range: 43.5 to 81.0 L/min). In adult patients with severe asthma, mean peak inspiratory flow through the ELLIPTA inhaler was 96.6 L/min (range: 72.4 to 124.6 L/min). In pediatric patients with asthma aged 5 to 11 years, mean peak inspiratory flow through the ELLIPTA inhaler was 60.6 L/min (range: 36.3 to 82.5 L/min). The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile.</Description>
</NDC>
<NDC>
<NDCCode>66993-136-97</NDCCode>
<PackageDescription>1 TRAY in 1 CARTON (66993-136-97) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER</PackageDescription>
<NDC11Code>66993-0136-97</NDC11Code>
<ProductNDC>66993-136</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Fluticasone Furoate And Vilanterol</ProprietaryName>
<NonProprietaryName>Fluticasone Furoate And Vilanterol</NonProprietaryName>
<DosageFormName>POWDER</DosageFormName>
<RouteName>RESPIRATORY (INHALATION)</RouteName>
<StartMarketingDate>20220523</StartMarketingDate>
<MarketingCategoryName>NDA AUTHORIZED GENERIC</MarketingCategoryName>
<ApplicationNumber>NDA204275</ApplicationNumber>
<LabelerName>Prasco Laboratories</LabelerName>
<SubstanceName>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</SubstanceName>
<StrengthNumber>200; 25</StrengthNumber>
<StrengthUnit>ug/1; ug/1</StrengthUnit>
<Pharm_Classes>Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-06-15</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20220523</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Fluticasone Furoate/Vilanterol ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta2-adrenergic agonist (LABA), indicated for: 1 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1.1), 2 the maintenance treatment of asthma in patients aged 5 years and older. (1.2).</IndicationAndUsage>
<Description>Fluticasone Furoate/Vilanterol ELLIPTA is an inhalation powder drug product for delivery of a combination of fluticasone furoate (an ICS) and vilanterol (a LABA) to patients by oral inhalation. Fluticasone furoate, a synthetic trifluorinated corticosteroid, has the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate and the following chemical structure. Fluticasone furoate is a white powder with a molecular weight of 538.6, and the empirical formula is C27H29F3O6S. It is practically insoluble in water. Vilanterol trifenatate has the chemical name triphenylacetic acid-4-{(1R)-2-[(6-{2-[2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) and the following chemical structure. Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C24H33Cl2NO5C20H16O2. It is practically insoluble in water. Fluticasone furoate/vilanterol ELLIPTA is a light grey and pale blue plastic inhaler containing 2 foil blister strips. Each blister on one strip contains a white powder blend of micronized fluticasone furoate (50, 100 or 200 mcg) and lactose monohydrate (12.5, 12.4 or 12.3 mg, respectively), and each blister on the other strip contains a white powder blend of micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (12.34 mg). The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece. Under standardized in vitro test conditions, fluticasone furoate/vilanterol ELLIPTA delivers 46, 92 or 184 mcg of fluticasone furoate and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds. In adult patients with obstructive lung disease and severely compromised lung function (COPD with FEV1/FVC <70% and FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory failure), mean peak inspiratory flow through the ELLIPTA inhaler was 66.5 L/min (range: 43.5 to 81.0 L/min). In adult patients with severe asthma, mean peak inspiratory flow through the ELLIPTA inhaler was 96.6 L/min (range: 72.4 to 124.6 L/min). In pediatric patients with asthma aged 5 to 11 years, mean peak inspiratory flow through the ELLIPTA inhaler was 60.6 L/min (range: 36.3 to 82.5 L/min). The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile.</Description>
</NDC>
<NDC>
<NDCCode>70100-810-02</NDCCode>
<PackageDescription>6 PACKAGE in 1 CARTON (70100-810-02) / 1 KIT in 1 PACKAGE * 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (70100-710-01) * 10 mL in 1 VIAL, PLASTIC (0409-4887-17) </PackageDescription>
<NDC11Code>70100-0810-02</NDC11Code>
<ProductNDC>70100-810</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Ic-green</ProprietaryName>
<NonProprietaryName>Indocyanine Green</NonProprietaryName>
<DosageFormName>KIT</DosageFormName>
<StartMarketingDate>20260415</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA011525</ApplicationNumber>
<LabelerName>Renew Pharmaceuticals Limited</LabelerName>
<Status>Active</Status>
<LastUpdate>2026-04-15</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20260415</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older (1.1). Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older (1.2). Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer (1.3). Ophthalmic angiography in adults and pediatric patients (1.4).</IndicationAndUsage>
<Description>IC-GREEN (indocyanine green for injection) is an optical imaging agent for intravenous or interstitial use. Each vial contains 10 mg or 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder. IC-GREEN has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP. The chemical name for Indocyanine Green is 1 HBenz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt. Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula. Indocyanine green has a peak spectral absorption at 805 nm in blood.</Description>
</NDC>
<NDC>
<NDCCode>83021-033-01</NDCCode>
<PackageDescription>250 mL in 1 BOTTLE, SPRAY (83021-033-01) </PackageDescription>
<NDC11Code>83021-0033-01</NDC11Code>
<ProductNDC>83021-033</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona New Even</ProprietaryName>
<NonProprietaryName>Lactic Acid, Citric Acid, Glycolic Acid</NonProprietaryName>
<DosageFormName>LOTION</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221013</StartMarketingDate>
<EndMarketingDate>20270113</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>FD&C BLUE NO. 1; LACTIC ACID; POLYOXYL 40 HYDROGENATED CASTOR OIL; TROLAMINE; .ALPHA.-HEXYLCINNAMALDEHYDE; LINALOOL, (+/-)-; BENZOIC ACID; PHENOXYETHANOL; GLYCOLIC ACID; WATER; ALLANTOIN; DEHYDROACETIC ACID; DIETHYLENE GLYCOL MONOETHYL ETHER; FRAGRANCE 13576; LIMONENE, (+)-; PROPYLENE GLYCOL</SubstanceName>
<StrengthNumber>.0005; 2.348125; 1.25; .5; .0150375; .0041025; .625; 2.5; 1.220625; 228.15635; .75; .25; .75; .075; .022755; 10.5</StrengthNumber>
<StrengthUnit>g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; mL/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL</StrengthUnit>
<Pharm_Classes>Acidifying Activity [MoA], Ammonium Ion Binding Activity [MoA], Nitrogen Binding Agent [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221013</StartMarketingDatePackage>
<EndMarketingDatePackage>20270113</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-064-01</NDCCode>
<PackageDescription>200 mL in 1 TUBE (83021-064-01) </PackageDescription>
<NDC11Code>83021-0064-01</NDC11Code>
<ProductNDC>83021-064</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Vital Line</ProprietaryName>
<NonProprietaryName>Hydrolyzed Collagen</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20230223</StartMarketingDate>
<EndMarketingDate>20261020</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>PHENOXYETHANOL; FRAGRANCE 13576; ETHYLHEXYLGLYCERIN; AVOBENZONE; .BETA.-SITOSTEROL; HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW); LINOLEIC ACID; TOCOPHEROL; MALVA SYLVESTRIS FLOWERING TOP; PAPAVER RHOEAS FLOWER; MEDIUM-CHAIN TRIGLYCERIDES; SHEA BUTTER; LINOLENIC ACID; POLYGLYCERYL-4 ISOSTEARATE; HEXYL LAURATE; WHITE WAX; HYDROGENATED CASTOR OIL; AMILOXATE; CETYL PEG/PPG-10/1 DIMETHICONE (HLB 4); SQUALANE; WATER; GLYCERIN; CETEARYL ETHYLHEXANOATE</SubstanceName>
<StrengthNumber>1.8; .8; .2; 2; .01; .2; .16; .08; .06; .04; 34; 4; .04; 3; 2.7; 1; 4; 4; 3; .01; 125.88; 7; 4</StrengthNumber>
<StrengthUnit>g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-08-31</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230223</StartMarketingDatePackage>
<EndMarketingDatePackage>20261020</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-187-01</NDCCode>
<PackageDescription>200 mL in 1 TUBE (83021-187-01) </PackageDescription>
<NDC11Code>83021-0187-01</NDC11Code>
<ProductNDC>83021-187</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Vital Line</ProprietaryName>
<NonProprietaryName>Hydrolyzed Elastin, Hydrolysed Collagen, Cocoglycerides</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221025</StartMarketingDate>
<EndMarketingDate>20261020</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>AVOBENZONE; PHENOXYETHANOL; FRAGRANCE 13576; DEHYDROACETIC ACID; HYDROLYZED BOVINE ELASTIN (BASE; 1000 MW); OCTINOXATE; COCO-GLYCERIDES; GLYCERIN; HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW); CETOSTEARYL ALCOHOL; MEDIUM-CHAIN TRIGLYCERIDES; CETYL ALCOHOL; .ALPHA.-HEXYLCINNAMALDEHYDE; WATER; BENZOIC ACID; CENTAUREA CYANUS FLOWER; VIOLA ODORATA; LIMONENE, (+)-; POTASSIUM PHOSPHATE, UNSPECIFIED FORM; .BETA.-CITRONELLOL, (R)-; ISOMETHYL-.ALPHA.-IONONE; BUTYLATED HYDROXYTOLUENE</SubstanceName>
<StrengthNumber>2; 1.62; .98; .14; .03; 5; 8; 6.94; .6; 12.58; 12; 4; .16; 140; .24; .05; .05; .038; .006; .0056; .0054; .005</StrengthNumber>
<StrengthUnit>g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; mL/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL; g/200mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221025</StartMarketingDatePackage>
<EndMarketingDatePackage>20261020</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-401-50</NDCCode>
<PackageDescription>50 mL in 1 BOTTLE (83021-401-50) </PackageDescription>
<NDC11Code>83021-0401-50</NDC11Code>
<ProductNDC>83021-401</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Glycolic Acid, Citric Acid, Lactic Acid, Kojic Acid</NonProprietaryName>
<DosageFormName>LIQUID</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221104</StartMarketingDate>
<EndMarketingDate>20270701</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M006</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>GLYCOLIC ACID; KOJIC ACID; HEXYLRESORCINOL; ASCORBYL GLUCOSIDE; LACTIC ACID; PHENOXYETHANOL; PROPYLENE GLYCOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; ALCOHOL; AMMONIA; ISOPROPYL ALCOHOL; WATER; ETHYLHEXYLGLYCERIN; SALICYLIC ACID</SubstanceName>
<StrengthNumber>17; 2.5; 1; .25; 5; .225; .5; .34875; 6.3; 2.75; .75; 7.333; .025; 1</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL</StrengthUnit>
<Pharm_Classes>Acidifying Activity [MoA]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221104</StartMarketingDatePackage>
<EndMarketingDatePackage>20270701</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-402-50</NDCCode>
<PackageDescription>50 mL in 1 BOTTLE, GLASS (83021-402-50) </PackageDescription>
<NDC11Code>83021-0402-50</NDC11Code>
<ProductNDC>83021-402</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Azelaic Acid, Salicylic Acid</NonProprietaryName>
<DosageFormName>LIQUID</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221026</StartMarketingDate>
<EndMarketingDate>20270908</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M006</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>AZELAIC ACID; POLYETHYLENE GLYCOL 400; PROPYLENE GLYCOL; ISOPROPYL ALCOHOL; WATER; SALICYLIC ACID; ALCOHOL</SubstanceName>
<StrengthNumber>7; 4.9965; 10; 2.7; 1.62; 1; 22.68</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; mL/50mL</StrengthUnit>
<Pharm_Classes>Decreased Protein Synthesis [PE], Decreased Sebaceous Gland Activity [PE]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221026</StartMarketingDatePackage>
<EndMarketingDatePackage>20270908</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-495-20</NDCCode>
<PackageDescription>20 mL in 1 BOTTLE, DROPPER (83021-495-20) </PackageDescription>
<NDC11Code>83021-0495-20</NDC11Code>
<ProductNDC>83021-495</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Proteoglycan, Glycerin, Butylene Glycol</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221025</StartMarketingDate>
<EndMarketingDate>20270902</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>PHENOXYETHANOL; XANTHAN GUM; BENZOIC ACID; WATER; BUTYLENE GLYCOL; PROPANEDIOL; POLYSORBATE 20; EDETIC ACID; PROTEOGLYCAN 4; FRAGRANCE 13576; GLYCERIN; DEHYDROACETIC ACID</SubstanceName>
<StrengthNumber>.162; .08; .024; 16.4578; .46; .4; .2; .0002; .002; .03; 2; .014</StrengthNumber>
<StrengthUnit>g/20mL; g/20mL; g/20mL; mL/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Ammonium Ion Binding Activity [MoA], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Lead Chelating Activity [MoA], Lead Chelator [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221025</StartMarketingDatePackage>
<EndMarketingDatePackage>20270902</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-501-20</NDCCode>
<PackageDescription>20 mL in 1 BOTTLE, DROPPER (83021-501-20) </PackageDescription>
<NDC11Code>83021-0501-20</NDC11Code>
<ProductNDC>83021-501</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Ferulic Acid, Vitamin C, Dmae</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221013</StartMarketingDate>
<EndMarketingDate>20280124</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>ALCOHOL; GLYCERIN; LECITHIN, SOYBEAN; WATER; MALONDIALDEHYDE; POLYOXYL 35 CASTOR OIL; FRAGRANCE 13576; PEG-8 CAPRYLIC/CAPRIC GLYCERIDES; FERULIC ACID</SubstanceName>
<StrengthNumber>.96; .02; .12; 14.26; 2; .18; .02; 2; .1</StrengthNumber>
<StrengthUnit>mL/20mL; g/20mL; g/20mL; mL/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221013</StartMarketingDatePackage>
<EndMarketingDatePackage>20280124</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-551-50</NDCCode>
<PackageDescription>50 mL in 1 BOTTLE (83021-551-50) </PackageDescription>
<NDC11Code>83021-0551-50</NDC11Code>
<ProductNDC>83021-551</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubismed</ProprietaryName>
<NonProprietaryName>Spf 50 Broad Spectrum Protection Fluid Emulsion</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221015</StartMarketingDate>
<EndMarketingDate>20270429</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M020</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; GLYCERIN; LINOLENIC ACID; TROMETHAMINE; OCTOCRYLENE; BUTYLATED HYDROXYTOLUENE; PROPYLENE GLYCOL; WATER; FRAGRANCE 13576; CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED); .ALPHA.-TOCOPHEROL; POLY(METHYL METHACRYLATE; 450000 MW); AVOBENZONE; TITANIUM DIOXIDE; PHENOXYETHANOL; POLYETHYLENE GLYCOL 400; LINOLEIC ACID; SILICON DIOXIDE; ANHYDROUS CITRIC ACID; ASCORBYL PALMITATE; ASCORBIC ACID; OCTISALATE; BEMOTRIZINOL; DIMETHICONE; OCTINOXATE; BUTYLENE GLYCOL; C20-22 ALCOHOLS; CHLORPHENESIN</SubstanceName>
<StrengthNumber>.025; .005; .00275; .22; 1.8; .0018; 2.5; 27.55; .3; .075; .006; 2.1; 1.8; .425; .35; .14225; .49725; .575; .00025; .00125; .00025; 1.8; 1.45; 1.25; 3.5982; 2.5; .3375; .1</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL</StrengthUnit>
<Pharm_Classes>Acidifying Activity [MoA], Allergens [CS], Anti-coagulant [EPC], Ascorbic Acid [CS], Calcium Chelating Activity [MoA], Calculi Dissolution Agent [EPC], Cell-mediated Immunity [PE], Decreased Coagulation Factor Activity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Vitamin C [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221015</StartMarketingDatePackage>
<EndMarketingDatePackage>20270429</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-553-60</NDCCode>
<PackageDescription>60 mL in 1 JAR (83021-553-60) </PackageDescription>
<NDC11Code>83021-0553-60</NDC11Code>
<ProductNDC>83021-553</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Dmae, Zirhafirm</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20230113</StartMarketingDate>
<EndMarketingDate>20280306</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>ALOE VERA LEAF; LINALOOL, (+/-)-; EUGENOL; PROPANEDIOL; BENZYL ALCOHOL; CETOSTEARYL ALCOHOL; DICAPRYLYL ETHER; SORBIC ACID; XANTHAN GUM; .BETA.-CITRONELLOL, (R)-; GLYCERYL MONOSTEARATE; FRAGRANCE 13576; SALICYLIC ACID; JUJUBE SEED; LECITHIN, SOYBEAN; BAICALIN; LEUZEA CARTHAMOIDES ROOT; WATER; LIMONENE, (+)-; HYDROXYCITRONELLAL; TOCOPHEROL; GLYCERIN; DECYL OLEATE; SHEA BUTTER</SubstanceName>
<StrengthNumber>5.988; .0006; .0006; 2.496; .456; 1.2; 1.5; .024; .18; .0006; 2.4; .114; .09; .048; .036; .012; .012; 33.2616; .006; .0024; .0018; 3.036; 3.9; 2.1</StrengthNumber>
<StrengthUnit>g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; mL/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL; g/60mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Pediculicide [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230113</StartMarketingDatePackage>
<EndMarketingDatePackage>20280306</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-617-05</NDCCode>
<PackageDescription>5 mL in 1 VIAL, GLASS (83021-617-05) </PackageDescription>
<NDC11Code>83021-0617-05</NDC11Code>
<ProductNDC>83021-617</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona</ProprietaryName>
<NonProprietaryName>Peg-40 Hydrogenated Castor Oil, Propylene Glycol, Allantoin</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221021</StartMarketingDate>
<EndMarketingDate>20270920</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M006</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>PROPYLPARABEN; ALLANTOIN; PANTHENOL; FD&C YELLOW NO. 5; PROPYLENE GLYCOL; ARCTIUM LAPPA ROOT; METHYLPARABEN; TIOXOLONE; WATER; ALCOHOL; POLYOXYL 40 HYDROGENATED CASTOR OIL; YEAST, UNSPECIFIED; ASCORBYL PALMITATE; RIBOFLAVIN; ETHYLPARABEN; TOCOPHEROL; CITRAL; LIMONENE, (+)-; POWDERED CELLULOSE; ISOPROPYL ALCOHOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; LEVOMENOL; FARNESOL; FRAGRANCE 13576; PHENOXYETHANOL; BUTYLPARABEN; NIACINAMIDE</SubstanceName>
<StrengthNumber>.0000001; .0125; .0025; .00001; .0069; .000035; .00500065; .01; 3.12515585; 1.756; .02; .01725; .00005; .000003; .00000015; .000001; .000097; .002095; .0003; .0006; .017; .0045; .0005; .01; .000003; .00000025; .0001</StrengthNumber>
<StrengthUnit>g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; mL/5mL; mL/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL; g/5mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Fungal Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221021</StartMarketingDatePackage>
<EndMarketingDatePackage>20270920</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-624-10</NDCCode>
<PackageDescription>10 mL in 1 BOTTLE, WITH APPLICATOR (83021-624-10) </PackageDescription>
<NDC11Code>83021-0624-10</NDC11Code>
<ProductNDC>83021-624</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Regul Oil</ProprietaryName>
<NonProprietaryName>Peg-40 Hydrogenated Castor Oil, Propylene Glycol, Arctium Majus Root Extract</NonProprietaryName>
<DosageFormName>CONCENTRATE</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221021</StartMarketingDate>
<EndMarketingDate>20270707</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M006</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>ALCOHOL; POLYOXYL 40 HYDROGENATED CASTOR OIL; YEAST, UNSPECIFIED; PROPYLENE GLYCOL; ARCTIUM LAPPA ROOT; ALLANTOIN; POWDERED CELLULOSE; PROPYLPARABEN; TOCOPHEROL; FRAGRANCE 13576; ETHYLPARABEN; ASCORBYL PALMITATE; WATER; TIOXOLONE; LEVOMENOL; HYDROXYETHYL CELLULOSE, UNSPECIFIED; ISOPROPYL ALCOHOL; FARNESOL; METHYLPARABEN; PANTHENOL; PHENOXYETHANOL; BUTYLPARABEN; NIACINAMIDE; RIBOFLAVIN; CITRAL; LIMONENE, (+)-; FD&C YELLOW NO. 5</SubstanceName>
<StrengthNumber>3.512; .04; .0345; .0138; .00007; .025; .0006; .0000002; .000002; .02; .0000003; .0001; 6.2503117; .02; .009; .034; .0012; .001; .0100013; .005; .000006; .0000005; .0002; .000006; .000194; .00419; .00002</StrengthNumber>
<StrengthUnit>mL/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; mL/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL; g/10mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Dietary Proteins [CS], Fungal Proteins [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Non-Standardized Food Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221021</StartMarketingDatePackage>
<EndMarketingDatePackage>20270707</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-686-50</NDCCode>
<PackageDescription>50 mL in 1 BOTTLE (83021-686-50) </PackageDescription>
<NDC11Code>83021-0686-50</NDC11Code>
<ProductNDC>83021-686</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Protective Line</ProprietaryName>
<NonProprietaryName>Ethylhexyl Methoxycinnamate, Butyl Methoxydibenzoylmethane, Ethylhexyl Salicylate, Octocrylene</NonProprietaryName>
<DosageFormName>CREAM</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221102</StartMarketingDate>
<EndMarketingDate>20280309</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M020</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>OCTINOXATE; TITANIUM DIOXIDE; CHLORPHENESIN; OCTISALATE; BUTYLENE GLYCOL; PROPYLENE GLYCOL; POLY(METHYL METHACRYLATE; 450000 MW); WATER; SILICON DIOXIDE; BUTYLATED HYDROXYTOLUENE; DIMETHICONE; CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE; C20-22 ALCOHOLS; FRAGRANCE 13576; CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED); TROMETHAMINE; BEMOTRIZINOL; POLYETHYLENE GLYCOL 400; ASCORBYL PALMITATE; PHENOXYETHANOL; OCTOCRYLENE; AVOBENZONE; LINOLENIC ACID; ASCORBIC ACID; TOCOPHEROL; LINOLEIC ACID; GLYCERIN</SubstanceName>
<StrengthNumber>3.5982; .425; .1; 1.8; 2.5; 2.5; 2.1; 27.55; .575; .0018; 1.25; .025; .3375; .3; .075; .22; 1.45; .14225; .00125; .35; 1.8; 1.8; .00275; .00025; .006; .49725; .005</StrengthNumber>
<StrengthUnit>g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; mL/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL; g/50mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Ascorbic Acid [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC], Skin Barrier Activity [PE], Vitamin C [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221102</StartMarketingDatePackage>
<EndMarketingDatePackage>20280309</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>83021-692-01</NDCCode>
<PackageDescription>250 mL in 1 BOTTLE, SPRAY (83021-692-01) </PackageDescription>
<NDC11Code>83021-0692-01</NDC11Code>
<ProductNDC>83021-692</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Anubis Barcelona Total Hydrating</ProprietaryName>
<NonProprietaryName>Betaine, Glycerin, Polysorbate 20</NonProprietaryName>
<DosageFormName>LOTION</DosageFormName>
<RouteName>TOPICAL</RouteName>
<StartMarketingDate>20221013</StartMarketingDate>
<EndMarketingDate>20270912</EndMarketingDate>
<MarketingCategoryName>OTC MONOGRAPH FINAL</MarketingCategoryName>
<ApplicationNumber>M016</ApplicationNumber>
<LabelerName>ANUBIS COSMETICS SL</LabelerName>
<SubstanceName>BETAINE; FRAGRANCE 13576; FD&C BLUE NO. 1; BENZOIC ACID; GLYCERIN; PHENOXYETHANOL; ETHYLHEXYLGLYCERIN; POLYSORBATE 20; WATER; IMIDUREA</SubstanceName>
<StrengthNumber>5; .125; .00025; 1.75; 5; 2.25; .125; 2.75; 232.139; .75</StrengthNumber>
<StrengthUnit>g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; g/250mL; mL/250mL; g/250mL</StrengthUnit>
<Pharm_Classes>Allergens [CS], Allergens [CS], Ammonium Ion Binding Activity [MoA], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Methylating Activity [MoA], Methylating Agent [EPC], Nitrogen Binding Agent [EPC], Non-Standardized Chemical Allergen [EPC], Standardized Chemical Allergen [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2023-09-05</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20221013</StartMarketingDatePackage>
<EndMarketingDatePackage>20270912</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
</NDCList>